RU2008127882A - Лечение пищевода барретта - Google Patents
Лечение пищевода барретта Download PDFInfo
- Publication number
- RU2008127882A RU2008127882A RU2008127882/14A RU2008127882A RU2008127882A RU 2008127882 A RU2008127882 A RU 2008127882A RU 2008127882/14 A RU2008127882/14 A RU 2008127882/14A RU 2008127882 A RU2008127882 A RU 2008127882A RU 2008127882 A RU2008127882 A RU 2008127882A
- Authority
- RU
- Russia
- Prior art keywords
- secretase
- inhibitor
- notch pathway
- partially
- specified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Способ, по меньшей мере, частичного уменьшения имеющихся у животного патологических признаков пищевода Барретта, включающий, по меньшей мере, частичное ингибирование активации пути Notch у указанного животного. ! 2. Способ по п.1, где указанная активация пути Notch, по меньшей мере, частично ингибируется, по меньшей мере, частичным уменьшением опосредованной лигандом активации Notch. ! 3. Способ по п.1 или 2, где указанная активация пути Notch, по меньшей мере, частично ингибируется введением ингибитора γ-секретазы. ! 4. Способ по п.1, где указанный ингибитор γ-секретазы вводится в виде перорального препарата. ! 5. Применение ингибитора пути Notch при изготовлении лекарственного средства для лечения пищевода Барретта. ! 6. Применение по п.5, где указанный ингибитор пути Notch представляет собой ингибитор γ-секретазы. ! 7. Применение по п.5 или 6, где указанное лекарственное средство представляет собой пероральное лекарственное средство. ! 8. Способ по п.1, где указанный ингибитор γ-секретазы непосредственно блокирует активность γ-секретазы. ! 9. Применение по п.6, где указанный ингибитор γ-секретазы блокирует активность γ-секретазы.
Claims (9)
1. Способ, по меньшей мере, частичного уменьшения имеющихся у животного патологических признаков пищевода Барретта, включающий, по меньшей мере, частичное ингибирование активации пути Notch у указанного животного.
2. Способ по п.1, где указанная активация пути Notch, по меньшей мере, частично ингибируется, по меньшей мере, частичным уменьшением опосредованной лигандом активации Notch.
3. Способ по п.1 или 2, где указанная активация пути Notch, по меньшей мере, частично ингибируется введением ингибитора γ-секретазы.
4. Способ по п.1, где указанный ингибитор γ-секретазы вводится в виде перорального препарата.
5. Применение ингибитора пути Notch при изготовлении лекарственного средства для лечения пищевода Барретта.
6. Применение по п.5, где указанный ингибитор пути Notch представляет собой ингибитор γ-секретазы.
7. Применение по п.5 или 6, где указанное лекарственное средство представляет собой пероральное лекарственное средство.
8. Способ по п.1, где указанный ингибитор γ-секретазы непосредственно блокирует активность γ-секретазы.
9. Применение по п.6, где указанный ингибитор γ-секретазы блокирует активность γ-секретазы.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05077832.3 | 2005-12-09 | ||
| EP05077832A EP1795198A1 (en) | 2005-12-09 | 2005-12-09 | Treatment of Barret's esophagus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008127882A true RU2008127882A (ru) | 2010-01-20 |
| RU2432163C2 RU2432163C2 (ru) | 2011-10-27 |
Family
ID=36000965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008127882/15A RU2432163C2 (ru) | 2005-12-09 | 2006-12-08 | Лечение пищевода барретта |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090306049A1 (ru) |
| EP (2) | EP1795198A1 (ru) |
| JP (1) | JP2009518392A (ru) |
| CN (1) | CN101370506A (ru) |
| AU (1) | AU2006323317A1 (ru) |
| BR (1) | BRPI0619495A2 (ru) |
| CA (1) | CA2633166A1 (ru) |
| MX (1) | MX2008007422A (ru) |
| NZ (1) | NZ569217A (ru) |
| RU (1) | RU2432163C2 (ru) |
| WO (1) | WO2007067048A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070265246A1 (en) * | 2004-11-10 | 2007-11-15 | Clevers Johannes C | Treatment of an Intestinal Adenoma and/or Adenocarcinoma by Inhibition of Notch Pathway Activation |
| CN101569864B (zh) * | 2008-04-29 | 2011-08-03 | 中山大学 | 手性磺胺类有机小分子催化剂及其应用 |
| SG10201508118WA (en) * | 2010-09-30 | 2015-11-27 | Agency Science Tech & Res | Methods and reagents for detection and treatment of esophageal metaplasia |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| CA2835325A1 (en) * | 2011-05-06 | 2012-11-15 | Monk Street Partners Llc | Compositions and methods for the prevention of esophageal cancer |
| WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| JP2015529251A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｎｏｔｃｈ阻害剤としての三環系複素環式化合物 |
| JP2015533811A (ja) | 2012-09-21 | 2015-11-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｎ−置換ビス（フルオロアルキル）１，４−ベンゾジアゼピノン化合物 |
| EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| EP2897947B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| JP2015531792A (ja) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | １，４−ベンゾジアゼピノン化合物のプロドラッグ |
| US9492469B2 (en) | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| RU2005133206A (ru) * | 2003-03-28 | 2006-05-10 | Янссен Фармацевтика Н.В. (Be) | Производные бензо {1,2,5} тиадиазола |
| GB0312365D0 (en) * | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| WO2005007107A2 (en) * | 2003-07-11 | 2005-01-27 | University Of Massachusetts | Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| GB2411115A (en) * | 2004-02-19 | 2005-08-24 | Medical Res Council | Retinoic acid antagonists for the treatment of oesophageal disorders |
| WO2005095610A1 (en) * | 2004-03-31 | 2005-10-13 | Agt Biosciences Limited | Nucleic acid expressed in the hypothalamus or muscle tissue and uses thereof in diagnoses |
| US20070265246A1 (en) * | 2004-11-10 | 2007-11-15 | Clevers Johannes C | Treatment of an Intestinal Adenoma and/or Adenocarcinoma by Inhibition of Notch Pathway Activation |
-
2005
- 2005-12-09 EP EP05077832A patent/EP1795198A1/en not_active Withdrawn
-
2006
- 2006-12-08 MX MX2008007422A patent/MX2008007422A/es not_active Application Discontinuation
- 2006-12-08 BR BRPI0619495-8A patent/BRPI0619495A2/pt not_active IP Right Cessation
- 2006-12-08 RU RU2008127882/15A patent/RU2432163C2/ru not_active IP Right Cessation
- 2006-12-08 JP JP2008544277A patent/JP2009518392A/ja not_active Withdrawn
- 2006-12-08 CA CA002633166A patent/CA2633166A1/en not_active Abandoned
- 2006-12-08 US US12/086,195 patent/US20090306049A1/en not_active Abandoned
- 2006-12-08 WO PCT/NL2006/000627 patent/WO2007067048A1/en active Application Filing
- 2006-12-08 EP EP06824302A patent/EP1968602A1/en not_active Withdrawn
- 2006-12-08 NZ NZ569217A patent/NZ569217A/en not_active IP Right Cessation
- 2006-12-08 CN CNA2006800526383A patent/CN101370506A/zh active Pending
- 2006-12-08 AU AU2006323317A patent/AU2006323317A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008007422A (es) | 2008-10-29 |
| US20090306049A1 (en) | 2009-12-10 |
| RU2432163C2 (ru) | 2011-10-27 |
| CN101370506A (zh) | 2009-02-18 |
| JP2009518392A (ja) | 2009-05-07 |
| WO2007067048A1 (en) | 2007-06-14 |
| EP1795198A1 (en) | 2007-06-13 |
| BRPI0619495A2 (pt) | 2011-10-04 |
| CA2633166A1 (en) | 2007-06-14 |
| EP1968602A1 (en) | 2008-09-17 |
| AU2006323317A1 (en) | 2007-06-14 |
| NZ569217A (en) | 2010-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008127882A (ru) | Лечение пищевода барретта | |
| TW200635582A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| MXPA05011208A (es) | Uso de ivermectina para el tratamiento de desordenes dermatologicos. | |
| UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| SE0202462D0 (sv) | Novel use | |
| NO20064186L (no) | Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| UA96575C2 (en) | Process for the preparation of olmesartan medoxomil | |
| DE502004008819D1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| WO2004100893A3 (en) | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof | |
| ATE410152T1 (de) | Therapeutisches system mit amoxicillin und clavulansäure | |
| NO20031410L (no) | Anvendelse av distamycinderivater for fremstilling av medikamenter | |
| RU2010146309A (ru) | Фармацевтическая композиция для лечения фибромиалгии | |
| GEP201606538B (en) | Preoperative treatment of post operative pain | |
| DE602006019830D1 (de) | Tetrahydro- und dihydrochinazolinone | |
| SE0000303D0 (sv) | Novel compounds | |
| IS6555A (is) | Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni | |
| DE60300683D1 (de) | Prucaloprid-n-oxid | |
| DE602005017629D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis | |
| EA200100876A3 (ru) | Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12 | |
| MXPA05008883A (es) | Agente terapeutico para enfermedad hemorroidal. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20111209 |